Core Insights - Pelthos Therapeutics Inc. reported a significant growth in net product revenue for ZELSUVMI, achieving $9.1 million in the fourth quarter of 2025, which is a 28% increase from the previous quarter [1][8] - The total net product revenue for ZELSUVMI from its launch in July 2025 through December 31, 2025, reached $16.2 million, contributing to a total revenue of $16.8 million for the year [1][4] Revenue and Sales Performance - A total of 8,948 ZELSUVMI units were prescribed by 2,712 unique prescribers in fiscal year 2025, with a remarkable 129% quarter-over-quarter increase in units dispensed from 2,716 in Q3 2025 to 6,232 in Q4 2025 [2][4] - The company anticipates continued strong growth for ZELSUVMI in 2026, supported by recent capital raises and acquisitions [5] Financial Overview - The cost of goods sold for the fourth quarter of 2025 was $1.7 million, down from $2.3 million in the third quarter, indicating improved cost management [8] - Selling, general, and administrative (SG&A) expenses decreased from $19.6 million in Q3 2025 to $18.5 million in Q4 2025, reflecting a 6% reduction [8] - The operating loss improved from approximately $15.4 million in Q3 2025 to $12.0 million in Q4 2025, indicating progress towards positive cash flow [8] Strategic Acquisitions - In November 2025, Pelthos completed the acquisition of XEPI®, a topical treatment for impetigo, which addresses a significant unmet need in pediatric care [4][5] - The company also announced the acquisition of XEGLYZE® in January 2026, a treatment for head lice, further expanding its portfolio in pediatric infectious diseases [4][5] Capital and Financing - Pelthos raised $18.0 million through private convertible notes financing in November 2025, which facilitated the acquisition of XEPI and supported the commercial rollout of ZELSUVMI [4][5] - In January 2026, the company secured a $50.0 million senior secured term loan facility, drawing $30.0 million at closing, enhancing its financial flexibility [4][5] Market Position and Future Outlook - The company is well-positioned to capitalize on large addressable markets with its three products: ZELSUVMI, XEPI, and XEGLYZE, which target similar pediatric demographics [5] - The expansion of the sales force, adding 14 representatives, aims to enhance market penetration and revenue growth [4][5]

Core Insights - Pelthos Therapeutics Inc. reported strong commercial performance for ZELSUVMI, generating $7.1 million in net revenues during its first quarter of operations [1][5] - The company has successfully launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, with 2,716 units prescribed by 1,169 unique prescribers in Q3 2025 [1][5] - The acquisition of XEPI adds a complementary product to Pelthos' portfolio, targeting the same pediatric market as ZELSUVMI, enhancing revenue potential [3][5] Financial Performance - For the three months ended September 30, 2025, Pelthos reported total revenue of $7.4 million, with net product revenues from ZELSUVMI at $7.1 million [10] - The company incurred a net loss of $16.2 million, translating to a loss of $5.30 per share [9][10] - Cash and cash equivalents as of September 30, 2025, stood at $14.2 million, reflecting a significant increase from $513,000 in December 2024 [7] Operational Highlights - The commercial launch of ZELSUVMI exceeded expectations, with strong market uptake and continued growth anticipated in Q4 2025 [3][5] - The company completed a merger to form Pelthos Therapeutics and raised $50.1 million in an equity private placement to support ZELSUVMI's launch [5] - An additional $18 million in private convertible notes financing was closed in November 2025 to facilitate the purchase and relaunch of XEPI and expedite ZELSUVMI's commercial rollout [5] Market Context - ZELSUVMI addresses a significant unmet need in treating molluscum contagiosum, primarily affecting children, while XEPI targets antibiotic-resistant skin infections, further solidifying Pelthos' position in the pediatric dermatology market [3][5] - The combined addressable markets for ZELSUVMI and XEPI present substantial revenue opportunities for Pelthos, leveraging existing commercial relationships and infrastructure [3][5]